Business Wire·Oct 27, 2025, 7:05 AM ET

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

CareDx, Inc. appointed Jeffrey John Teuteberg, MD, as Chief Medical Officer effective October 1, 2025.
Dr. Teuteberg brings over two decades of clinical transplantation experience, including senior leadership roles at Stanford University & the University of Pittsburgh Medical Center.
He is board certified in Heart Failure/Cardiac Transplantation & Cardiovascular Medicine & has served as Section Chief of Heart Failure, Cardiac Transplant, & Mechanical Circulatory Support at Stanford since 2017.
Dr. Teuteberg served as President of the International Society for Heart and Lung Transplantation (ISHLT) & held prominent roles in the American Society of Transplantation (AST).
He acted as principal investigator for the Surveillance HeartCare Outcomes Registry (SHORE) study to advance noninvasive rejection surveillance science.
Dr. Teuteberg will lead CareDx's global Medical Affairs activities, including Medical Directors, Medical Science Liaisons, & clinical research operations.
CareDx is a precision medicine company headquartered in Brisbane, California, focused on solutions for transplant patients & caregivers.
The press release includes forward-looking statements subject to risks detailed in CareDx's SEC filings, including the 2024 Annual Report on Form 10-K filed on February 28, 2025, & the Q2 2025 Quarterly Report on Form 10-Q filed on August 6, 2025.